Metabolic syndrome, such as high blood sugar and blood pressure, linked to increased risk of cancer

Publicly released:
International
Image by PDPics from Pixabay
Image by PDPics from Pixabay

People with persistent and worsening metabolic syndrome, which includes conditions such as high blood pressure, high blood sugar, excess abdominal fat, and abnormal cholesterol, may be at higher risk of developing various types of cancer, according to international researchers. The study included 44,115 adults in China, and categorised participants based on the trends in their health from 2006 to 2010. They found that, compared to those with low levels of metabolic issues that remained stable, those with higher and increasing scores relating to metabolic syndrome had a higher risk of developing cancer, including breast, endometrial, kidney, colorectal, and liver cancer. 

Media release

From: Wiley

Does worsening metabolic syndrome increase the risk of developing cancer?  

Study reveals a significant link, suggesting that managing metabolic syndrome may help prevent cancer. 

New research indicates that individuals with persistent and worsening metabolic syndrome—which encompasses conditions such as high blood pressure, elevated blood sugar, excess abdominal fat, and abnormal cholesterol—face an elevated risk of developing various types of cancer. The findings are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society. 

In the study, 44,115 adults in China with an average age of 49 years were categorized into 4 different trajectories based on trends from 2006 (the time of the first physical exam) to 2010: 10.56% exhibited a low-stable pattern and maintained low metabolic syndrome scores; 40.84% exhibited a moderate-low pattern and maintained moderate to low metabolic syndrome scores; 41.46% exhibited a moderate-high pattern and consistently maintained moderate to high metabolic syndrome scores; and 7.14% exhibited an elevated-increasing pattern in which initially elevated metabolic syndrome scores increased over time.  

During the follow-up period of 2010–2021, with a median follow-up of 9.4 years, there were 2,271 cancer diagnoses among participants. Compared with participants with a low-stable trajectory pattern, those with an elevated-increasing trajectory pattern had 1.3-, 2.1-, 3.3-, 4.5-, 2.5-, and 1.6-times higher risks of developing any cancer, breast cancer, endometrial cancer, kidney cancer, colorectal cancer, and liver cancer, respectively. 

Even when the low-stable, moderate-low, and moderate-high trajectory pattern groups were combined, the elevated-increasing trajectory pattern group had higher risks of developing all cancer types. 

Also, participants with persistently high metabolic syndrome scores and concurrent chronic inflammation had the highest risks of developing breast, endometrial, colon, and liver cancer, whereas the risk of kidney cancer was predominantly observed among participants with persistently high scores but without chronic inflammation. 

“This research suggests that proactive and continuous management of metabolic syndrome may serve as an essential strategy in preventing cancer,” said senior author Han-Ping Shi, MD, PhD, of Capital Medical University, in Beijing. “Our study can guide future research into the biological mechanisms linking metabolic syndrome to cancer, potentially resulting in targeted treatments or preventive strategies. Formal evaluation of these interventions will be needed to determine if they are able to modulate cancer risk.” 

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research Wiley, Web page The URL will go live after the embargo lifts.
Journal/
conference:
Cancer
Research:Paper
Organisation/s: Beijing Shijitan Hospital of Capital Medical University, China
Funder: This work was supported by the National Key Research and Development Program (2022YFC2009600 and 2022YFC2009601); Laboratory for Clinical Medicine, Capital Medical University (2023‐SYJCLC01); and National Multidisciplinary Cooperative Diagnosis and Treatment Capacity Project for Major Diseases: Comprehensive Treatment and Management of Critically Ill Elderly Inpatients (No. 2019 YLFW) to Hanping Shi. The funders had no role in considering the study design or in the collection, analysis, interpretation of data, writing of the report, or decision to submit the article for publication. This study obtained ethical approval from the ethics committees of Kailuan General Hospital and Beijing Shijitan Hospital, and it adhered to the principles outlined in the Declaration of Helsinki. Written informed consent was obtained from participants or their legal representatives. The Kailuan Study was retrospectively registered in the Chinese Clinical Trial Register on February 12, 2020 (ChiCTR2000029767; https://www.chictr.org.cn/showprojEN.html? proj=48316). The manuscript’s guarantor affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.
Media Contact/s
Contact details are only visible to registered journalists.